Revised forecast
Fiscal year ending March 2027 · Cumulative first quarterPrevious forecast published 14 May 2026The bar length represents the relative magnitude of change, based on the item that changed the most in this document. The percentage change shown by the dotted line is calculated from the two reported figures because the company did not provide the rate.
Sales are expected to exceed the initial forecast because orders for semiconductor-related materials and other products have remained strong. Meanwhile, the main factors behind the lower profit forecast were the greater-than-expected time required to validate and improve manufacturing procedures during the transition of development-stage projects to mass production, and higher costs resulting from lower operating rates in the pharmaceutical field during the first quarter. A valuation loss of ¥97 million was recorded, and cost of sales also increased.
Valuation loss of ¥97 million
| Item | Details |
|---|---|
| Net Sales | ¥2,000 million → ¥2,118 million（+5.9%） |
| Operating profit | ¥95 million → ¥51 million（-46.0%） |
| Ordinary income | ¥90 million → ¥48 million（-46.6%） |
| Profit attributable to owners of the parent | ¥63 million → ¥41 million（-34.9%） |
| Net income per share | ¥8.14 → ¥5.3 |
| Fiscal Period Covered | Fiscal year ending March 2027 |
| Period Covered | Cumulative first quarter |
| Publication date of previous forecast | 14 May 2026 |
| Previous-period results | First quarter of the fiscal year ended March 2026: sales of ¥1,694 million, operating loss of ¥9 million, ordinary loss of ¥11 million, net loss of ¥11 million, and net loss per share of ¥1.46. |
| Reason for the revision | Sales are expected to exceed the initial forecast because orders for semiconductor-related materials and other products have remained strong. Meanwhile, the main factors behind the lower profit forecast were the greater-than-expected time required to validate and improve manufacturing procedures during the transition of development-stage projects to mass production, and higher costs resulting from lower operating rates in the pharmaceutical field during the first quarter. A valuation loss of ¥97 million was recorded, and cost of sales also increased. |
| Details and amount of extraordinary loss | Valuation loss of ¥97 million |
Items this document does not state (2)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.Sales are expected to exceed the forecast, as orders for semiconductor-related materials and other products in the functional materials field have been strong. However, profit forecasts were lowered because validating and improving manufacturing procedures during the transition of development-stage projects to mass production required more work hours than expected, while lower operating rates in the pharmaceutical field during the first quarter pushed up costs. A valuation loss of ¥97 million was also recorded.